Ensign Peak Advisors
RPTX

Ensign Peak Advisors’s Repare Therapeutics RPTX Stock Holding History

Ensign Peak Advisors’s Portfolio RPTX Stock Details RPTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-344,328
Closed -$1.62M – 1733
2024
Q1 		$1.62M Hold
344,328
– – ﹤0.01% 1016
2023
Q4 		$2.51M Hold
344,328
– – 0.01% 824
2023
Q3 		$4.16M Buy
344,328
+73,425
+27% +$758K 0.01% 622
2023
Q2 		$2.87M Buy
270,903
+186,300
+220% +$1.92M 0.01% 753
2023
Q1 		$832K Hold
84,603
– – ﹤0.01% 1397
2022
Q4 		$1.24M Sell
84,603
-6,200
-7% -$92.7K ﹤0.01% 1006
2022
Q3 		$1.1M Buy
90,803
+5,480
+6% +$70.5K ﹤0.01% 1016
2022
Q2 		$1.19M Sell
85,323
-27,971
-25% -$329K ﹤0.01% 1038
2022
Q1 		$1.61M Buy
113,294
+20,970
+23% +$311K ﹤0.01% 960
2021
Q4 		$1.95M Buy
92,324
+72,924
+376% +$1.72M ﹤0.01% 968
2021
Q3 		$509K Hold
19,400
– – ﹤0.01% 1620
2021
Q2 		$605K Hold
19,400
– – ﹤0.01% 1562
2021
Q1 		$595K Hold
19,400
– – ﹤0.01% 1573
2020
Q4 		$666K Hold
19,400
– – ﹤0.01% 1537
2020
Q3 		$597K Buy
19,400
+17,400
+870% +$461K ﹤0.01% 1484
2020
Q2 		$62K Buy
+2,000
New +$64.2K ﹤0.01% 1655

Other funds holding RPTX

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
ACM
Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Ensign Peak Advisors's RPTX Position: Q2 2024 in Review

Ensign Peak Advisors sold out of Repare Therapeutics (RPTX) in Q2 2024, closing a stake of 344,328 shares — an estimated $1.62M sold.

Ensign Peak Advisors first reported a position in RPTX in Q2 2020 and held it in 16 quarters. The position peaked at $4.16M in Q3 2023. 61 funds tracked by Wall St. Rank hold RPTX as of Q2 2024.

  • Ensign Peak Advisors reported no remaining Repare Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Ensign Peak Advisors sold 344,328 Repare Therapeutics shares in Q2 2024, an estimated $1.62M.
  • Ensign Peak Advisors first reported a position in Repare Therapeutics in Q2 2020 and held it in 16 quarters.
  • Ensign Peak Advisors's Repare Therapeutics position peaked at $4.16M in Q3 2023.
  • 61 funds tracked by Wall St. Rank held Repare Therapeutics as of Q2 2024.

Based on Ensign Peak Advisors's 13F filing for Q2 2024, filed 13 Aug 2024.